- Home
- ANL vs CGTX Comparison
ANL vs CGTX Comparison
Compare ANL & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | CGTX |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.9M | 94.5M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANL | CGTX |
|---|---|---|
| Price | $8.82 | $1.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $16.00 | $3.33 |
| AVG Volume (30 Days) | 214.2K | ★ 624.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $0.22 |
| 52 Week High | $12.09 | $3.83 |
Technical Indicators
Market Signals| Indicator | ANL | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.38 | 52.08 |
| Support Level | $1.37 | $1.00 |
| Resistance Level | $10.15 | $1.19 |
| Average True Range (ATR) | 0.97 | 0.07 |
| MACD | -0.27 | 0.02 |
| Stochastic Oscillator | 56.12 | 80.56 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.